The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...
The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.
Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.
Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...
A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.
A new review article highlights a number of roles for B1 cells, including antibody secretion and the stimulation of CD4+ cells. B cells are known to play a role in systemic lupus erythematosus (SLE), ...
Objective To investigate the relationship between adverse childhood experiences (ACEs) and health outcomes in childhood-onset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results